
GR3027
CAS No. 2089238-18-4
GR3027 ( GR-3027 | Golexanolone )
产品货号. M13263 CAS No. 2089238-18-4
GR3027 (Golexanolone) 是一种 GABA-A 受体调节类固醇拮抗剂,可选择性拮抗四氢孕酮和 THDOC 等神经类固醇对 GABAA 受体的增强激活。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥7857 | 有现货 |
![]() ![]() |
50MG | ¥16038 | 有现货 |
![]() ![]() |
100MG | ¥20250 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称GR3027
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述GR3027 (Golexanolone) 是一种 GABA-A 受体调节类固醇拮抗剂,可选择性拮抗四氢孕酮和 THDOC 等神经类固醇对 GABAA 受体的增强激活。
-
产品描述GR3027 (Golexanolone) is a GABA-A receptor modulating steroid antagonist that selectively antagonizes the enhanced activation of GABAA receptors by neurosteroids such as allopregnanolone and THDOC; inhibits α1β2γ2L receptor 29 ± 5% of THDOC enhancement of the GABA response, does not antagonize the effect of GABA at the GABAA receptor; during the specific conditions used for the different receptors, IC50=250 nM for the α1β2γ2L GABAA receptor and 350 nM for the α5β3γ2L GABAA receptor; restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy.Sleep Disorder Phase 2 Clinical.
-
体外实验——
-
体内实验——
-
同义词GR-3027 | Golexanolone
-
通路Membrane Transporter/Ion Channel
-
靶点GAT
-
受体GAT
-
研究领域Neurological Disease
-
适应症Sleep Disorder
化学信息
-
CAS Number2089238-18-4
-
分子量329.484
-
分子式C21H31NO2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC[C@]1([C@](CC/2)([H])[C@]3([H])CC[C@@]4([H])C[C@](O)(C#C)CC[C@]4(C)[C@@]3([H])CC1)C2=N\O
-
化学全称(17E)-3α-ethynyl-17-(hydroxyimino)-5α-androstan-3β-ol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Johansson M, et al. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G400-9.
2. Johansson M, et al. J Steroid Biochem Mol Biol. 2016 Jun;160:98-105.
3. Johansson M, et al. Psychopharmacology (Berl). 2018 May;235(5):1533-1543.
4. Patent WO 2008/063128.